CA07987C2040 - Common Stock
BELLUS HEALTH INC
NASDAQ:BLU (6/28/2023, 8:00:02 PM)
After market: 14.74 0 (0%)14.74
0 (0%)
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
BELLUS HEALTH INC
275 Armand-Frappier Blvd
Laval QUEBEC H7V 4A7
P: 14506804500.0
CEO: Roberto Bellini
Employees: 74
Website: https://bellushealth.com/
/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Here you can normally see the latest stock twits on BLU, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: